Myant

Founder and CEO Tony Chahine directs both the strategic roadmap and operational execution. While Myant is not structured as a family office or traditional investment firm, Chahine controls capital allocation across R&D, clinical partnerships, and manufacturing expansion. The firm has raised external venture funding over multiple rounds, but Chahine remains the central figure governing deployment of resources.

Myant originates partnerships through direct engagement with hospital systems and automotive OEMs seeking integrated biometric-monitoring capabilities. The firm's long-term collaborations with Mayo Clinic and Canada's University Health Network serve as reference implementations that attract additional health systems. On the industrial side, Myant leverages its textile-computing patent portfolio to negotiate component-supply and licensing arrangements directly with vehicle-interior divisions.

It operates as all three in a vertically integrated stack. The company knits conductive yarns into fabrics, embeds miniaturized electronics at the textile level, and runs the Skiin software platform that interprets the resulting biosignal data. This blurs traditional category lines: Myant owns the manufacturing of its sensor garments, the firmware that processes signals, and the cloud-based analytics that deliver clinical insights.

Myant's commercial model has shifted toward institutional channels. Early consumer-facing Skiin garments were positioned for general wellness, but the firm now focuses on enterprise healthcare deployments — remote patient monitoring for hospitals and clinical-trial support for pharma — plus licensing its textile-electronics technology to automotive and apparel manufacturers rather than pursuing mass-market retail.

Skiin Connected Health was spun out as a related entity focusing specifically on remote patient monitoring applications, but Myant Inc. retains control of the core textile-computing intellectual property and manufacturing operations. The structure allows Skiin Connected Health to pursue healthcare-specific partnerships and regulatory pathways while Myant continues to serve industrial and broader platform-development functions from its Toronto campus.

Textile-based medical sensors must satisfy both medical-device regulations and apparel-textile standards, a dual compliance path that adds complexity. Myant's clinical collaborations with institutions like Mayo Clinic are designed in part to generate the validation data required for FDA and Health Canada clearances. The firm has pursued these clearances iteratively, aligning particular garment applications with specific regulatory classifications.

The core differentiator is form factor and manufacturing ownership. Whoop and Oura sell discrete hardware devices — wristbands and rings — that users consciously wear. Myant's technology lives invisibly inside everyday clothing, capturing data continuously without a separate object to remember. Furthermore, Myant manufactures its own conductive textiles and knitting processes in-house, whereas the device-centric competitors rely on contract manufacturers for rigid electronics, giving Myant a different intellectual-property moat rooted in textile science rather than consumer-electronics hardware.